Truist Financial Corp Puma Biotechnology, Inc. Transaction History

Truist Financial Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$2.85 - $6.58 $313,220 - $723,155	-109,902 Closed	0 $0
Q3 2021 Nov 05, 2021	BUY	$6.63 - $9.39 $11,052 - $15,653	1,667 Added 1.54%	109,902 $770,000
Q2 2021 Aug 16, 2021	BUY	$8.98 - $11.6 $62,940 - $81,304	7,009 Added 6.92%	108,235 $994,000
Q1 2021 May 17, 2021	BUY	$9.38 - $13.63 $411,472 - $597,907	43,867 Added 76.48%	101,226 $984,000
Q4 2020 Nov 19, 2021	SELL	$7.78 - $12.13 $17,217 - $26,843	-2,213 Reduced 3.71%	57,359 $589,000
Q4 2020 Feb 18, 2021	BUY	$7.78 - $12.13 $131,100 - $204,402	16,851 Added 39.44%	59,572 $612,000
Q3 2020 Nov 13, 2020	BUY	$9.5 - $11.14 $79,220 - $92,896	8,339 Added 24.25%	42,721 $431,000
Q2 2020 Aug 14, 2020	BUY	$7.01 - $13.24 $22,074 - $41,692	3,149 Added 10.08%	34,382 $359,000
Q1 2020 May 15, 2020	BUY	$6.28 - $14.57 $84,547 - $196,155	13,463 Added 75.76%	31,233 $264,000
Q4 2019 Feb 14, 2020	BUY	$6.5 - $10.73 $115,505 - $190,672	17,770 New	17,770 $155,000

103

29M

60.6K

16.3K

Ticker PBYI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,556,000
Market Cap $134M
Description
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for...

Get notified when there are updates to the investment portfolio of Truist Financial Corp, based on Form 13F filings with the SEC.

Stay updated on Truist Financial Corp with notifications on news.